General Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trialsBy Healthcare Propulsion StaffNovember 2, 20260 Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today…
